Shariatgorji, Reza http://orcid.org/0000-0001-9484-0921
Nilsson, Anna
Fridjonsdottir, Elva
Strittmatter, Nicole http://orcid.org/0000-0003-1277-9608
Dannhorn, Andreas http://orcid.org/0000-0002-1087-4057
Svenningsson, Per
Goodwin, Richard J. A. http://orcid.org/0000-0001-5699-8488
Odell, Luke R.
Andrén, Per E. http://orcid.org/0000-0002-4062-7743
Funding for this research was provided by:
Vetenskapsrådet (2018–03320, 2018–05501)
Hjärnfonden (FO2018-0292)
Stiftelsen för Strategisk Forskning (RIF14-0078)
Science for Life Laboratory
Uppsala Universitet
Article History
Received: 16 October 2020
Accepted: 5 March 2021
First Online: 2 June 2021
Competing interests
: N.S, A.D. and R.J.A.G. are full-time salaried employees, own stocks of AstraZeneca and performed this study as part of their regular duties. None of the authors received any form of royalty or further financial compensation from AstraZeneca for publishing these protocols. L.R.O., A.N., R. S. and P.E.A. are co-founders and shareholders in Tag-ON AB and have filed a patent application ‘Reactive desorption and/or laser ablation ionization matrices and use thereof’, no. PCT/SE2019/050197 (patent pending).